Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-15 Activated CIK Cells in Relapsing Acute Leukemia or MDS After Allogeneic SCT
NCT02752243Phase 2Unknown
- Start
- Mar 2016
- Primary completion
- Mar 2023
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in acute leukemia and myelodysplastic syndrome (MDS). Primary endpoints: Acute Graft versus Host Disease and Chronic Graft versus Host Disease. Status: unknown.
02
Conditions
acute leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02752243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752243.